home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

252.86 -5.52 (-2.14%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

7 Growth Stocks Poised to Thrive in a Post-Fed Pivot World ↗

December 28, 2023

If the Federal Reserve loosens the monetary spigot, these companies could represent the growth stocks to buy now.

Via InvestorPlace

Topics Economy

Jazz Pharmaceuticals' Post-Traumatic Stress Disorder Drug Disappoints In Mid-Stage Study ↗

December 22, 2023

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced top-line results from the Phase 2 trial of JZP150, an investigational small molecule selective fatty acid amide hydrolase (FAAH) inhibitor, on efficacy...

Via Benzinga

3 No-Brainer Stocks to Buy With $500 Right Now ↗

December 20, 2023

You don't need a mountain of cash to build wealth on Wall Street.

Via The Motley Fool

Japan Approves Marijuana-Derived Medicines, Adopt 7-Year Prison Sentences For Recreational Use ↗

December 06, 2023

Japan’s Parliament passed a bill Wednesday legalizing medical products derived from cannabis.

Via Benzinga

Australian MPs Admit They Tried Cannabis, Signaling Policy Reform & Epidiolex For Seizures Approved In Canada ↗

November 30, 2023

Around 8% of Australians are using medical marijuana either occasionally or regularly, according to a recent survey of 1,000 participants conducted by consumer insights company Antenna, reported...

Via Benzinga

Topics Cannabis

Analyst Ratings for Jazz Pharmaceuticals ↗

November 29, 2023

Via Benzinga

Jazz Pharmaceuticals: Q3 Earnings Insights ↗

November 08, 2023

Via Benzinga

Where Jazz Pharmaceuticals Stands With Analysts ↗

September 29, 2023

Via Benzinga

3 Top-Rated Biotech Stocks That Analysts Are Loving Now ↗

November 28, 2023

Investing in biotech stocks can be tricky, but analysts have bullish outlooks on these three, promising companies.

Via InvestorPlace

Pot Stocks: Values Or Traps? ↗

November 22, 2023

Pot stocks were the hottest thing around five years ago but after catching a bid during the pandemic, the stocks have now plunged to multi-year lows.

Via Talk Markets

Topics Cannabis

3 Biotech Stocks That Could Be Millionaire Makers ↗

November 22, 2023

Many biotech stocks offer exciting long-term growth prospects.

Via The Motley Fool

Police Boss Turned Cannabis Reform Advocate, MMJ Legalization In Japan And More Global Updates ↗

November 16, 2023

Medical Cannabis-Based Epidiolex Advances Through Japan's Legislature Earlier this week, Japanese policymakers gave the green light to a measure to legalize medical products derived from cannabis,...

Via Benzinga

Topics Cannabis

3 No-Brainer Stocks to Buy With $200 Right Now ↗

November 15, 2023

A modest amount of money can go a long way when it's invested in inexpensive, game-changing businesses.

Via The Motley Fool

Autifony Announces Exclusive Global License and Collaboration Agreement with Jazz Pharmaceuticals on Two Ion Channel Targets for Neurological Disorders

November 14, 2023

From Autifony Therapeutics Ltd

Via Business Wire

7 Healthcare Stocks That Are Poised to Become the Next Unicorns ↗

November 09, 2023

Discover healthcare stocks with remarkable potential for growth and "unicorn" status in the ever-evolving world of healthcare investments.

Via InvestorPlace

Cannabis Cash Burn Concerns? Sell These 7 Overbought Stocks Now. ↗

November 07, 2023

These overbought cannabis stocks are teetring on the edge as the sector is navigating through uncharted waters.

Via InvestorPlace

Topics Cannabis

FDA Report On Its 50 Years In Cannabis Research, Signals A Boost In Medical Marijuana Prospects ↗

November 03, 2023

Researchers with the Food and Drug Administration (FDA) reported Wednesday on the agency’s 50 years of experience with marijuana research. In an article titled “FDA’s 50

Via Benzinga

Topics Cannabis

Ireland Reimburses Medical Marijuana-Based Drug For Chemotherapy-Induced Nausea And Vomiting ↗

October 30, 2023

Althea Group Holdings Limited (ASX: AGH), an Australian manufacturer of cannabis-based medicines and recreational cannabis products confirmed that Ireland’s Primary Care Reimbursement...

Via Benzinga

Topics Cannabis

Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030

October 25, 2023

EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NASDAQ:JAZZ),(NASDAQ:EXEL),(NASDAQ:AMGN),(NASDAQ:REGN) EQNX::TICKER_END

Via FinancialNewsMedia

Europe's High: UK Parents Need NHS Help For Daughter's Seizures, THC MMJ Flowers In Switzerland & More ↗

October 24, 2023

Luxembourg: Medical Marijuana Shortage Due To Supplier Change

Via Benzinga

Topics Cannabis Supply Chain

Cannabis Stocks Dip: How Rising Interest Rates Impact Your Portfolio ↗

October 23, 2023

On Friday, cannabis stocks traded lower with the overall market. Marketfy analyst Michael Berger will be monitoring how the sector performs this week.

Via Benzinga

Topics Cannabis

Europe's High: Irish GPs Against Pot, Switzerland-Spain Share Data On Cannabis Clubs & More ↗

October 20, 2023

Denmark: Medical Marijuana Pilot Program Experience 90% Growth In 12 Months

Via Benzinga

Topics Cannabis

Jazz Pharmaceuticals Explores Asset Sale Option, Possibly Cannabinoid Business: Report ↗

October 20, 2023

Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) is reportedly exploring strategic options comprising a potential sale.

Via Benzinga

2 Top Biotech Stocks to Buy in October ↗

October 03, 2023

Growth catalysts lie ahead for both of these players.

Via The Motley Fool

5 Genius Safe Stocks to Buy for the 4th Quarter of 2023 ↗

October 02, 2023

These highly profitable, time-tested companies can deliver for their shareholders in any economic climate.

Via The Motley Fool

4 Perfect Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗

September 30, 2023

An 18% decline in the Nasdaq Composite from its all-time high means bargains still abound.

Via The Motley Fool

Topics Stocks

Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023 ↗

September 29, 2023

Via Benzinga

3 Cannabis Stocks That Should Be on Every Investor’s Radar This Fall ↗

September 27, 2023

The cannabis industry is a quiet place where huge upside potential is building up. As more regions legalize, cannabis stocks can soar.

Via InvestorPlace

Topics Cannabis

Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty

September 22, 2023

FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 22, 2023 – USA News Group – Despite the potential federal funding challenges due to the recent debt ceiling deal,...

Via FinancialNewsMedia

3 Biotech Stocks That Should Be on Every Investor’s Radar This Fall ↗

September 20, 2023

Even with higher for longer interest rates, drug discovery moves on. That’s why it’s still a good time to look for biotech stocks to buy.

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com